hrp0094p2-265 | Growth hormone and IGFs | ESPE2021

Growth response to growth hormone therapy in growth hormone deficient (GHD) children in relation to the distance between their height SDS (HtSDS) and their mid-parental height.

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed , Ahmed Hannah ,

Introduction: Mid-parental height (MPH) is a useful tool in the prediction of final adult height in normal children as well as those on growth hormone (GH) therapy. Aim of the study to evaluate the growth response to GH therapy in GHD children in relation to their MPH.Methods: This retrospective study included 22 short prepubertal children with GHD (peak GH<10 μg/l). They were followed in the Endocrine clinic be...

hrp0094p2-266 | Growth hormone and IGFs | ESPE2021

Linear growth and response to GH therapy in children with short stature with normal Growth hormone secretion: Comparison between children with delayed versus no delay in the bone age at diagnosis.

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , khalil Ahmed , Ahmed Hannah ,

Bone age (BA) continues to be a valuable tool in assessing children’s growth potential. Children with normal variant short stature can be subdivided into idiopathic short stature (ISS) (with no delay in BA versus chronological age (CA) and constitutional delay (CDG) (with delayed BA versus CA. The response of these two groups to GH therapy remains controversial.Aim, patients, and methods: We studied linear growth, weight gain, skeletal maturation, a...

hrp0094p2-267 | Growth hormone and IGFs | ESPE2021

Linear growth and response to GH therapy in children with GHD with normal IGF-I versus those with normal GH secretion associated with low IGFI at presentation.

Elsiddig Sohair , Soliman Ashraf , Khalil Ahmed , Alaaraj Nada , Ahmed Hannah ,

Introduction: Children with idiopathic short stature have linear growth impairment despite normal or even high levels of GH. In some of these children IGFI level is low (NGH + Low IGFI (IGFSDS<-1.5). It was observed that some children with GHD (Peak GH < 7 ng/dl after provocation) have normal IGFI levels (GHD +Normal IGFI). The linear growth of these two groups at presentation and their response to GH therapy was not studied well.<p class="abstext"...

hrp0094p2-268 | Growth hormone and IGFs | ESPE2021

Growth response to growth hormone therapy in short children in relation to their distance from mid-parental heights (MPHt).

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed , Ahmed Hannah ,

In normal children, mid parental height (MPH) is a useful tool in assessing children’s growth and in the prediction of their final adult height. However, this may not be true for short children, especially those with height SD (HtSDS) > - 1SDS compared to their mid-parental height SDS (MPHtSDS). The difference may indicate underlying pathology.Aim: To assess growth response (change in HtSDS) to GH therapy in short prepubertal ch...

hrp0092p2-11 | Adrenals and HPA Axis | ESPE2019

Long-term Prednisone versus Hydrocortisone Treatment in Children with Classic Congenital Adrenal Hyperplasia (CAH): A Controlled Study

Soliman Ashraf Tawfik , Abdel Meguid Ahmed Shayma Elsayed , Ramadan Magdy , Elawwa Ahmed , Said Abugabal Ahmed Mohamed , Ahmed Emam Mohamed Hassan

Background: Debate still exists about the safety of long-term use of prednisone (PD) versus hydrocortisone (HC) for treating children with CAH. Relatively slight supraphysiologic levels may be enough to blunt growth velocity, increase weight gain.Objectives of the study: We evaluated the anthropometric and biochemical effects of long-term PD versus HC treatment in children with CAH-21OHD.<p class="ab...

hrp0097p1-422 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Stüve-Wiedemann syndrome: an extremely rare disorder causing recurrent fractures.

Abdelmeguid Yasmine , Abdul-Aziz Ahmed

Background: Stüve-Wiedemann syndrome (SWS) is a rare autosomal recessive disorder, due to mutations in the leukemia inhibitory factor receptor (LIFR) gene. It is characterized by bowed-long bones, joint restrictions, dysautonomia, respiratory and feeding difficulties leading to death during infancy. In SWS survivors beyond 2 years of age, orthopedic problems are the main concern e.g. spinal deformations, osteoporosis and recurrent spontaneous fra...

hrp0092p1-113 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Delayed Puberty in A 16-Year-Old Male Associated with Gamma Aminobutyric Acid Capsule Supplements

Blackburn James , Senniappan Senthil , Ahmed Syed Harris

Background: Delayed puberty is defined as the absence of physical signs of puberty 2 to 2.5 standard deviations greater than the mean and affects 2% of the adolescent population. We present a male patient aged 16, presenting with delayed puberty. On direct questioning the patient revealed he had been taking regular Gamma-Aminobutyric Acid (GABA). These supplements appeared to suppress the hypothalamic-pituitary-gonadal (HPG) axis.<st...

hrp0092p1-126 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Longitudinal Changes in External Masculinisation Scores in Boys with XY Disorder of Sex Development (DSD)

Alimussina Malika , Kraria Loubna , Ahmed S Faisal

Introduction: Although, there are several studies that use the external masculinisation score (EMS) for numerical description of the external genitalia in infants with DSD, data on change in EMS in the routine clinical setting are lacking.Objectives: To determine the longitudinal change in EMS and its determinants in a cohort of boys with XY DSD in one specialist centre.Methods: Ob...

hrp0092p3-74 | Diabetes and Insulin | ESPE2019

Does Metformin Therapy Prolong the Honeymoon Period in Obese Adolescent with Hybrid Diabetes?

Hamed Noor , Elawwa Ahmed , Soliman Ashraf

Introduction: Hybrid diabetes is a challenging form od diabetes that need to be more studied. We describe a case of hybrid diabetes with a prolonged honeymoon due to the use of metformin.Case: Our patient is a 10 year old female patient who was diagnosed as type 2 DM on September 2017 at the age of 8 years. She was obese with BMI = 29.8 Kg/ m^2 with marked acanthosis nigricans. She had a patch of vitiligo on the face...

hrp0092p3-138 | GH and IGFs | ESPE2019

Factors Affecting Growth Response to Growth Hormone (GH) Therapy in Children with Short Stature and Normal GH and IGF-I Secretion and no Bone Age Delay

Elawwa Ahmed , Soliman Ashraf , Elalaily Rania

Background: There are inconsistencies in the results reported in a small number of previous studies into growth hormone (GH) treatment of short children with idiopathic short stature (ISS.Patients and Methods: Our study included 20 prepubertal (Tanner 1) or peri-pubertal (Tanner 2) children with short stature (HtSDS < -2) and/or HtSDS > 1SD below their mid parental height SD (MPHtSDS), slow Growth velocity( <...